Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma 3Urogenital Neoplasms 2Prostatic Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Male Urogenital Diseases 2Genital Neoplasms, Male 2Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases, Male 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

durvalumab 5Nivolumab 3Cyclophosphamide 3Cisplatin 3130-nm albumin-bound paclitaxel 3padeliporfin 2anlotinib 2Trabectedin 2Sunitinib 2Pemetrexed 2Docetaxel 2Chemoradiotherapy 2Carboplatin 2Bevacizumab 2sotorasib 1relatlimab 1relacorilant 1pembrolizumab 1patritumab 1palbociclib 1olaparib 1niraparib 1nintedanib 1montanide ISA 51 1golotimod 1genexol-PM 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Site × padeliporfin × Clear all
NCT00707356 2016-04-19

Study of WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
42 enrolled
Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00975429 2015-04-28

Study Using WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
86 enrolled
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡